What it's for (Indications)
- Pyrazinamide is a crucial first-line antitubercular agent indicated for the treatment of active tuberculosis caused by susceptible strains of *Mycobacterium tuberculosis*.
- It is never used as monotherapy but is always administered in combination with other antitubercular drugs, typically isoniazid, rifampin, and ethambutol, as part of a multi-drug regimen.
- Its inclusion is particularly vital during the initial intensive phase of short-course tuberculosis therapy, usually for the first two months.
- Pyrazinamide's unique bactericidal activity against *M.
- tuberculosis* residing within macrophages and caseous lesions, where the pH is acidic, significantly contributes to sterilizing the lesions and shortening the duration of treatment, thereby reducing the risk of relapse and the development of drug resistance.
- This makes it an indispensable component of modern TB treatment protocols, essential for achieving cure rates and preventing the spread of the disease.
- Its role is precisely defined within the World Health Organization (WHO) and national TB treatment guidelines.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of pyrazinamide must be carefully determined based on the patient's body weight and kidney function, and it is usually administered once daily or thrice weekly under direct observed therapy (DOT) to ensure adherence and optimize treatment outcomes. For adults, the typical daily dose ranges from 15 to 30 mg/kg, with a maximum recommended daily dose not exceeding 2 grams. When administered as part of an intermittent (e.g., thrice-weekly) regimen, higher individual doses may be used, such as 50 to 70 mg/kg, up to a maximum of 4 grams per dose. Dosage adjustments are crucial for patients with renal impairment; for instance, in those with creatinine clearance less than 30 mL/min, the dose should be reduced and administered three times per week, with close monitoring. Pyrazinamide is generally continued for the initial two months of a standard six-month short-course regimen for drug-susceptible tuberculosis. Strict adherence to prescribed dosages and duration is paramount to prevent treatment failure and the emergence of drug resistance, ensuring effective eradication of *Mycobacterium tuberculosis*. |
Safety & Warnings
Common Side Effects
- Pyrazinamide is associated with several adverse effects, with hepatotoxicity being the most significant and potentially severe.
- Elevated serum transaminases (AST, ALT) and bilirubin, ranging from asymptomatic elevations to severe, potentially fatal, hepatitis, are common.
- Other frequently reported side effects include gastrointestinal disturbances such as nausea, vomiting, anorexia, and abdominal pain.
- Hyperuricemia, resulting from pyrazinamide's inhibition of renal uric acid excretion, is very common and can lead to arthralgia (joint pain) or precipitate acute gouty arthritis in susceptible individuals.
- Less common but notable adverse effects include rash, photosensitivity, dysuria, malaise, fever, sideroblastic anemia, and thrombocytopenia.
- Neurological effects such as headache, dizziness, and mild confusion are rare but possible.
- Allergic reactions, though infrequent, can manifest as pruritus, urticaria, or more severe forms.
- Regular monitoring of liver function tests (LFTs) and uric acid levels is essential during therapy to detect and manage these side effects proactively, especially given the seriousness of liver damage and the potential for gout flares.
Serious Warnings
- Black Box Warning: Serious Warnings: HEPATOTOXICITY Pyrazinamide is associated with a significant risk of severe and potentially fatal hepatotoxicity. Liver injury, ranging from mild, asymptomatic elevations in serum transaminases to fulminant hepatitis, has been reported. The risk of developing pyrazinamide-induced liver damage increases with higher doses, longer durations of therapy, advanced age, pre-existing liver disease, chronic alcohol use, and concomitant administration of other hepatotoxic medications, including other antitubercular drugs. All patients receiving pyrazinamide must undergo baseline liver function testing, including serum transaminase (AST, ALT) and bilirubin levels, and these tests should be monitored at regular intervals throughout the treatment course, typically every 2-4 weeks or more frequently if clinically indicated, especially in high-risk individuals. Patients should be explicitly counselled on the signs and symptoms of liver injury (e.g., unusual fatigue, anorexia, nausea, dark urine, yellowing of skin or eyes) and instructed to seek immediate medical attention if these occur. If clinical or laboratory evidence of significant liver damage (e.g., transaminase elevations >3 times the upper limit of normal with symptoms, or >5 times the upper limit of normal without symptoms, or any elevation in bilirubin) emerges, pyrazinamide must be discontinued immediately. Continued administration in the presence of severe hepatic dysfunction can lead to irreversible liver failure and death. The decision to resume pyrazinamide after an episode of hepatotoxicity should be made with extreme caution and only after a thorough risk-benefit assessment by an expert, often necessitating a change in the antitubercular regimen.
- Several critical warnings are associated with pyrazinamide use, primarily revolving around its significant hepatotoxic potential.
- Patients should be closely monitored for signs and symptoms of liver injury, including fatigue, anorexia, nausea, dark urine, or jaundice, and liver function tests (AST, ALT, bilirubin) should be performed at baseline and at regular intervals throughout treatment.
- The risk of hepatotoxicity increases with dose, duration of therapy, advanced age, pre-existing liver disease, excessive alcohol consumption, and concomitant use of other hepatotoxic medications.
- Pyrazinamide frequently causes hyperuricemia; while often asymptomatic, it can exacerbate existing gout or trigger new episodes of acute gouty arthritis, requiring monitoring of uric acid levels and potentially requiring allopurinol for management.
- Pyrazinamide should be used with caution in patients with diabetes mellitus, as it may complicate glycemic control.
- Dosage adjustments are necessary in patients with significant renal impairment.
- Caution is also advised during pregnancy and lactation, with benefits weighed against potential risks, as adequate safety studies in these populations are limited.
- Patients should be advised to avoid excessive sun exposure due to the risk of photosensitivity.
How it Works (Mechanism of Action)
Pyrazinamide (PZA) is a prodrug that requires enzymatic activation by mycobacterial pyrazinamidase (PZase), encoded by the *pncA* gene, to its active form, pyrazinoic acid (POA). This conversion occurs primarily within the acidic environment of macrophages and caseous lesions, which are characteristic sites of *M. tuberculosis* infection, making PZA particularly effective against intracellular and dormant bacilli that are metabolically less active. The exact mechanisms of action of POA are multifaceted and not fully elucidated but are thought to involve: 1) Disruption of mycobacterial membrane integrity and energy metabolism by altering membrane potential and transport functions. 2) Inhibition of fatty acid synthase I (FAS I), an enzyme crucial for the synthesis of mycolic acids, essential components of the mycobacterial cell wall. 3) Disruption of CoA recycling and subsequent inhibition of trans-translation, leading to impaired protein synthesis. 4) Lowering of the intracellular pH to a level that is incompatible with *M. tuberculosis* growth and survival, by acidifying the cytoplasm. This unique activity profile against specific populations of bacilli makes pyrazinamide a vital component of multi-drug regimens, contributing significantly to the rapid sterilization of lesions and prevention of drug resistance.